The forthcoming results (expected in 2016) of the Prostate Testing for Cancer and Treatment (ProtecT) trial should provide further insight regarding survival and quality of life for patients with localized PCa diagnosed by PSA screening randomized to active monitoring, prostatectomy, or radiotherapy [30]. The gene discussed is KLK3; the disease is posterior cortical atrophy.